Transgene Appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
03 Dicembre 2020 - 06:00PM
Business Wire
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and
develops virus-based immunotherapeutics against cancer, announced
that the Board, at its meeting today, approved the appointment of
Hedi Ben Brahim as the Company’s new Chairman and CEO, effective
January 1st, 2021. Hedi Ben Brahim, who has been a member of
Transgene’s Board since May 2019, will replace Philippe Archinard.
Philippe Archinard has led the company since 2005 and will remain a
member of the Board of Transgene.
Alain Mérieux, honorary Chairman of Transgene, said: I
would like to thank Philippe Archinard for his commitment to
Transgene over the last 15 years. Under his leadership, the Company
has demonstrated the potential of virus-based immunotherapies and
developed world class innovative therapies that could be
game-changers in the field of cancer treatment. Based on these
achievements, I believe Transgene is now ideally placed to further
demonstrate the value of its approaches. I am confident that Hedi
Ben Brahim, together with Transgene’s highly skilled team, will
build on this strong foundation to generate multiple novel
virus-based immunotherapeutics that will both deliver important
clinical benefits to cancer patients and value for
shareholders.”
“It is a great honor and pleasure to join the Transgene
executive team. I am excited to take on this new role having seen
the significant potential of Transgene’s technology platforms and
their potential to bring improved clinical benefits to cancer
patients globally. Trangene’s Invir.IO™ and myvac® platforms are
significant breakthroughs in multi-armed oncolytic virus therapy
and individualized vaccines respectively. In addition, with the
positive Phase 1b/2 data of TG4001, Transgene has established the
relevance of its virus-based immunotherapy for HPV-positive cancer
patients. I look forward to continuing the development of this
promising candidate and further strengthen our exciting
immune-oncology pipeline”, added Hedi Ben Brahim.
Hedi Ben Brahim joins Transgene from Institut Mérieux
where he was Vice-President for Immunotherapy since September 2018.
In this role, he was the Chairman of ABL Inc., a contract research
& development, and contract biomanufacturing organization
(CRO/CMO). Prior to joining the Institut Mérieux, he was General
Manager at a subsidiary of Vallourec, a solutions provider to the
energy sector. Hedi began his career in the public sector at the
Ministry of the Economy, Action and Public Accounts, then at the
Ministry of Social Affairs and Health. He is a graduate of the
École Polytechnique and the École Nationale Supérieure des Mines de
Paris.
Philippe Archinard will become Executive Vice-President,
Technological Innovation and Scientific Partnerships at Institut
Mérieux. Philippe Archinard will remain Board Member of
Transgene.
Transgene’s Board has also been notified of the change of the
Director representing TSGH (Institut Mérieux); Dominique Takizawa
is to be replaced by Sandrine Flory as of January 1st, 2021.
Sandrine has been Chief Financial Officer of Institut Mérieux since
March 2020. She has spent 18 years at bioMérieux, in various
positions in finance. She was CFO for bioMérieux EMEA from 2014 to
2020. Prior to joining bioMérieux, Sandrine spent 9 years at
PriceWaterhouseCoopers in France and Australia. Sandrine holds a
master in Finance and Accounting and a MS in Business Valuation and
Transmission from the Université Lyon 2 (France).
***
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic
vaccines (TG4001 for the treatment of HPV-positive cancers, and
TG4050, the first individualized therapeutic vaccine based on the
myvac® platform) as well as two oncolytic viruses (TG6002 for the
treatment of solid tumors, and BT-001, the first oncolytic virus
based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters
the field of precision medicine with a novel immunotherapy that is
fully tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building
on its viral vector engineering expertise to design a new
generation of multifunctional oncolytic viruses. Transgene has an
ongoing Invir.IO™ collaboration with AstraZeneca. Additional
information about Transgene is available at: www.transgene.fr
Follow us on Twitter: @TransgeneSA
Disclaimer This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201203005801/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: Citigate Dewe Rogerson David Dible/Sylvie
Berrebi + 44 (0)20 7638 9571
transgene@citigatedewerogerson.com
Grafico Azioni Transgene (EU:TNG)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Transgene (EU:TNG)
Storico
Da Mar 2023 a Mar 2024